Additionally, patients with CAD had a higher prevalence of T2DM, arterial hypertension, and dyslipidemia, as well as increased fasting blood glucose and HbA1c compared to the noCAD group, while showing no difference in serum insulin, C-peptide, or lipid parameters (Table 1). This evidence concerns the gene INS and metabolic syndrome.